HA
DGX icon

Harfst & Associates’s Quest Diagnostics DGX Stock Holding History

Harfst & Associates’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,679
Closed -$356K – 104
2022
Q2 		$356K Sell
2,679
-2,759
-51% -$376K 0.1% 99
2022
Q1 		$744K Buy
5,438
+701
+15% +$97.7K 0.17% 84
2021
Q4 		$819K Sell
4,737
-371
-7% -$56.5K 0.21% 77
2021
Q3 		$742K Sell
5,108
-569
-10% -$83.3K 0.21% 82
2021
Q2 		$749K Sell
5,677
-192
-3% -$25.1K 0.22% 84
2021
Q1 		$753K Buy
+5,869
New +$723K 0.23% 88

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harfst & Associates's DGX Position: Q3 2022 in Review

Harfst & Associates sold out of Quest Diagnostics (DGX) in Q3 2022, closing a stake of 2,679 shares — an estimated $356K sold.

Harfst & Associates first reported a position in DGX in Q1 2021 and held it in 6 quarters. The position peaked at $819K in Q4 2021. 809 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

  • Harfst & Associates reported no remaining Quest Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Harfst & Associates sold 2,679 Quest Diagnostics shares in Q3 2022, an estimated $356K.
  • Harfst & Associates first reported a position in Quest Diagnostics in Q1 2021 and held it in 6 quarters.
  • Harfst & Associates's Quest Diagnostics position peaked at $819K in Q4 2021.
  • 809 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on Harfst & Associates's 13F filing for Q3 2022, filed 28 Oct 2022.